GLI1 and melanoma: Aberrant HH-GLI pathway activation, usually manifested by upregulation of GLI1 and PTCH1 expression, has been found in a multitude of human cancer types, including basal cell carcinoma (BCC), medulloblastoma (MB), glioma, melanoma, gastrointestinal, colon, breast, lung, liver, prostate and pancreatic cancer [108].